Ivermectin inhibits importin-α/β-dependent nuclear import of viral proteins
68,70,71,77, shows spike-ACE2 disruption at 1nM with microfluidic diffusional sizing
35, binds to glycan sites on the SARS-CoV-2 spike protein preventing interaction with blood and epithelial cells and inhibiting hemagglutination
38,78, shows dose-dependent inhibition of wildtype and omicron variants
33, exhibits dose-dependent inhibition of lung injury
58,63, may inhibit SARS-CoV-2 via IMPase inhibition
34, may inhibit SARS-CoV-2 induced formation of fibrin clots resistant to degradation
7, inhibits SARS-CoV-2 3CL
pro51, may inhibit SARS-CoV-2 RdRp activity
26, may minimize viral myocarditis by inhibiting NF-κB/p65-mediated inflammation in macrophages
57, may be beneficial for COVID-19 ARDS by blocking GSDMD and NET formation
79, may interfere with SARS-CoV-2's immune evasion via ORF8 binding
2, may inhibit SARS-CoV-2 by disrupting CD147 interaction
80-83, shows protection against inflammation, cytokine storm, and mortality in an LPS mouse model sharing key pathological features of severe COVID-19
56,84, may be beneficial in severe COVID-19 by binding IGF1 to inhibit the promotion of inflammation, fibrosis, and cell proliferation that leads to lung damage
6, may minimize SARS-CoV-2 induced cardiac damage
37,45, increases Bifidobacteria which play a key role in the immune system
85, has immunomodulatory
48 and anti-inflammatory
67,86 properties, and has an extensive and very positive safety profile
87.